# Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas

> **NCT00590954** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Malignant Gliomas
- CNS
- Brain Cancer
- Cancer

## Interventions

- **DRUG:** Perifosine

## Key facts

- **NCT ID:** NCT00590954
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2019-11-11
- **Final completion:** 2019-11-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-10-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00590954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00590954, "Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00590954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*